Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder

NCT03460652 is registered in ClinicalTrials.gov with Zevra Therapeutics as lead sponsor.

NCT NCT03460652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03460652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Lead sponsor
Zevra Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
March 13, 2018
Completion date
July 9, 2019
Enrollment
282 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

adhd